Placebo-controlled study of montelukast and budesonide on short-term growth in prepubertal asthmatic children
Placebo-controlled study of montelukast and budesonide on short-term growth in prepubertal asthmatic children
复制标题
DOI：
10.1002/ppul.20666
复制
发表时间：
2007-09-01
影响因子：
3.1
通讯作者：
Wolthers, Ole D.
中科院分区：
文献类型：
--
作者：
Pedersen, Soren;Agertoft, Lone;Wolthers, Ole D.
Background: Inhaled corticosterods and anti-leukotriene agents are widely used in the treatment of pediatric asthma. Although data on the effect of corticosteroids on growth are available, there are few such data on anti-leukotrien e agents. The aim of this study was to assess the influence of montelukast on short-term lower leg growth rate (LLGR) in prepubertal children with asthma. Methods: Forty-two boys (6- to 12-year old) and 29 girls (6- to 11-year old) with mild asthma were randomized to 1 of 2 crossover arms, with two treatment sequences per arm: montelukast 5 mg once daily/placebo or inhaled dry powder budesonide 200 mu g twice daily/ placebo. Budesonide was used as a positive control to ensure that the method was sensitive enough to detect a suppression of LLGR. The 3-week double-blind treatment period was followed by a 3-week washout. Primary outcome was LLGR over the 3-week treatment, measured by knemometry. Results: Ninety-four percent of patients completed the study. Mean LLGR was similar between patients receiving montelukast and placebo treatments: mean difference, -0.02 mm/ week [95% confidence interval -0.14, 0.11]. Mean LLGR in patients receiving budesonide was significantly less than for those receiving placebo (difference of -0.16 mm/week [-0.25, -0.06], P= 0.002). Mean LLGR was similar for patients taking placebo in the two arms (0.43 and 0.44 mm/ week). Conclusion Montelukast 5 mg did not significantly affect short-term LLGR in prepubertal children.
